DB:G061

Stock Analysis Report

Executive Summary

Genkyotex S.A., a biopharmaceutical company, develops oral small molecule NOX therapeutics.

Risk Analysis

Earnings are forecast to decline by an average of -86.8% per year for the next 3 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (€35M)



Snowflake Analysis

Mediocre balance sheet and overvalued.

Share Price & News

How has Genkyotex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: G061 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

18.2%

G061

-1.8%

DE Biotechs

0.1%

DE Market


1 Year Return

-72.9%

G061

7.2%

DE Biotechs

14.1%

DE Market

Return vs Industry: G061 underperformed the German Biotechs industry which returned 7.2% over the past year.

Return vs Market: G061 underperformed the German Market which returned 14.1% over the past year.


Shareholder returns

G061IndustryMarket
7 Day18.2%-1.8%0.1%
30 Day22.9%-2.9%0.2%
90 Day26.5%5.8%3.3%
1 Year-72.6%-72.9%7.5%7.2%17.6%14.1%
3 Yearn/a42.8%41.2%14.8%4.8%
5 Yearn/a11.6%9.3%22.2%5.4%

Price Volatility Vs. Market

How volatile is Genkyotex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Genkyotex undervalued compared to its fair value and its price relative to the market?

1.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate G061's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate G061's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: G061 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: G061 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate G061's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: G061 is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Genkyotex forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-86.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: G061 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: G061 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: G061 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if G061's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if G061's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if G061's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Genkyotex performed over the past 5 years?

-10.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: G061 is currently unprofitable.

Growing Profit Margin: G061 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if G061's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare G061's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: G061 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: G061 has a negative Return on Equity (-101.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Genkyotex's financial position?


Financial Position Analysis

Short Term Liabilities: G061's short term assets (€7.1M) exceed its short term liabilities (€4.3M).

Long Term Liabilities: G061's short term assets (€7.1M) exceed its long term liabilities (€1.3M).


Debt to Equity History and Analysis

Debt Level: G061's debt to equity ratio (20%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if G061's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: G061 has a low level of unsold assets or inventory.

Debt Coverage by Assets: G061's debt is covered by short term assets (assets are 3.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: G061 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: G061 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -12.6% each year


Next Steps

Dividend

What is Genkyotex's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate G061's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate G061's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if G061's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if G061's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of G061's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average board tenure


CEO

Elias Papatheodorou (50yo)

4.4yrs

Tenure

0

Mr. Ilias Papatheodorou, also known as Elias, has been the Chief Executive Officer at Genkyotex SA since September 30, 2015 and as its Director since February 28, 2017. Mr. Papatheodorou served as Chief Bu ...


Board Members

NamePositionTenureCompensationOwnership
Ilias Papatheodorou
CEO & Director4.4yrsno datano data
Karl-Heinz Krause
Founder & Member of Scientific Advisory Board0yrsno datano data
Stephane Verdood
Observer3yrsno datano data
Claudio Nessi
Chairman of the Board3yrsno datano data
Gilles Nobecourt
Director11.6yrsno datano data
Chihiro Yabe-Nishimura
Member of Scientific Advisory Board0yrsno datano data
Robert Clark
Chairman of Scientific Advisory Board0yrsno datano data
Catherine Moukheibir
Independent Director3yrsno datano data
Jesus Martin-Garcia
Director3yrsno datano data
David Lambeth
Member of Scientific Advisory Board0yrsno datano data

3.0yrs

Average Tenure

57.5yo

Average Age

Experienced Board: G061's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genkyotex SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genkyotex SA
  • Ticker: G061
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €34.505m
  • Shares outstanding: 11.54m
  • Website: https://www.genkyotex.com

Number of Employees


Location

  • Genkyotex SA
  • Forum 2 Archamps Technopole
  • 218, Avenue Marie Curie
  • Saint Julien En Genevois
  • Rhône-Alpes
  • 74166
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GKTXENXTPA (Euronext Paris)YesCommon SharesFREURMar 2017
G061DB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2017
GKTXPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURMar 2017

Biography

Genkyotex S.A., a biopharmaceutical company, develops oral small molecule NOX therapeutics. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company’s lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis, a fibrotic orphan disease, and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its second product candidate, GKT771, is a NOX1 inhibitor, which is undergoing preclinical testing targeting various pathways in angiogenesis, pain processing, and inflammation. The company’s research programs include brain penetrant NOX inhibitors to address CNS disorders and NOX inhibitors in oncology. Genkyotex S.A. has a partnership with Serum Institute of India Ltd for the development of prophylactic vaccines. The company was founded in 2006 and is based in Saint Julien En Genevois, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/18 23:14
End of Day Share Price2020/02/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.